Integrative transcriptomic and machine learning analyses identify DDX47 as a candidate diagnostic biomarker in acute myeloid leukemia

Background Acute myeloid leukemia (AML) is a highly heterogeneous hematological malignancy, and challenges remain in clinical diagnosis and the assessment of treatment response. This study aimed to identify candidate diagnostic biomarkers for AML and investigate their associations with the immune microenvironment and treatment response. Methods Transcriptomic profiles from The Cancer Genome Atlas (TCGA) and Genotype-Tissue Expression (GTEx) databases were integrated to identify candidate genes through differential expression analysis, weighted gene co-expression network analysis (WGCNA), and three machine learning algorithms. Diagnostic performance was evaluated using receiver operating characteristic (ROC) curve analysis, with external validation performed using the independent GSE9476 cohort. Associations between the candidate gene and immune cell infiltration and predicted drug sensitivity were further investigated. Its clinical relevance and potential functional role were subsequently evaluated through expression analyses of bone marrow samples from patients with AML and experiments involving AML cell lines treated with venetoclax following DDX47 knockdown. Results DDX47 was consistently identified as a candidate feature gene by three machine learning algorithms. DDX47 expression was significantly elevated in AML samples, with areas under the ROC curve (AUCs) of 0.824 in the discovery cohort and 0.862 in the independent validation cohort. DDX47 expression was associated with selected immune cell infiltration characteristics and the predicted sensitivity to multiple drugs. Analysis of clinical bone marrow samples further confirmed elevated DDX47 expression in patients with AML. In Molm-13 and THP-1 cells, DDX47 knockdown reduced venetoclax-induced cytotoxicity and apoptosis, suggesting that DDX47 may be involved in the response of AML cells to venetoclax. Conclusion This study identifies DDX47 as a candidate diagnostic biomarker for AML and revealed associations between its expression, immune microenvironment characteristics, and venetoclax response. These findings provide a basis for further investigation of the potential clinical relevance of DDX47 in AML diagnosis.

Authors

Institutions

Publication Details

Journal
Frontiers in Oncology
Published
2026-11-19
DOI
https://doi.org/10.3389/fonc.2026.1964212
Primary Topic
Acute Myeloid Leukemia Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Integrative transcriptomic and machine learning analyses identify DDX47 as a candidate diagnostic biomarker in acute myeloid leukemia

朱珣珣, Min Fang, Mingyan Zhang, Hao Zhang et al.
Frontiers in Oncology
Acute Myeloid Leukemia Research
article

Integrative transcriptomic and machine learning analyses identify DDX47 as a candidate diagnostic biomarker in acute myeloid leukemia

朱珣珣, Min Fang, Mingyan Zhang, Hao Zhang, Hui Wang
article en

Abstract

Background Acute myeloid leukemia (AML) is a highly heterogeneous hematological malignancy, and challenges remain in clinical diagnosis and the assessment of treatment response. This study aimed to identify candidate diagnostic biomarkers for AML and investigate their associations with the immune microenvironment and treatment response. Methods Transcriptomic profiles from The Cancer Genome Atlas (TCGA) and Genotype-Tissue Expression (GTEx) databases were integrated to identify candidate genes through differential expression analysis, weighted gene co-expression network analysis (WGCNA), and three machine learning algorithms. Diagnostic performance was evaluated using receiver operating characteristic (ROC) curve analysis, with external validation performed using the independent GSE9476 cohort. Associations between the candidate gene and immune cell infiltration and predicted drug sensitivity were further investigated. Its clinical relevance and potential functional role were subsequently evaluated through expression analyses of bone marrow samples from patients with AML and experiments involving AML cell lines treated with venetoclax following DDX47 knockdown. Results DDX47 was consistently identified as a candidate feature gene by three machine learning algorithms. DDX47 expression was significantly elevated in AML samples, with areas under the ROC curve (AUCs) of 0.824 in the discovery cohort and 0.862 in the independent validation cohort. DDX47 expression was associated with selected immune cell infiltration characteristics and the predicted sensitivity to multiple drugs. Analysis of clinical bone marrow samples further confirmed elevated DDX47 expression in patients with AML. In Molm-13 and THP-1 cells, DDX47 knockdown reduced venetoclax-induced cytotoxicity and apoptosis, suggesting that DDX47 may be involved in the response of AML cells to venetoclax. Conclusion This study identifies DDX47 as a candidate diagnostic biomarker for AML and revealed associations between its expression, immune microenvironment characteristics, and venetoclax response. These findings provide a basis for further investigation of the potential clinical relevance of DDX47 in AML diagnosis.

Frontiers in OncologyVol. 16
Tengzhou Central People's Hospital (CN), Affiliated Hospital of Jining Medical University (CN)
Acute Myeloid Leukemia Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon